TheraRadar
← Back
Data updated: Jul 17, 2026

INA PHARMS

Specialty

INA PHARMS is a specialty pharmaceutical company focused on Dermatology.

1963
Since
3
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

Upcoming FDA Decisions

Full Calendar →
Feb 27, 2027 — Zipalertinib

INA PHARMS's Key Drugs

INA PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

INA PHARMS's Recent FDA Approvals

New NDA/BLA approvals for INA PHARMS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

INA PHARMS's Therapeutic Areas

INA PHARMS's approved drugs and pipeline span 1 therapeutic area, led by Dermatology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Dermatology 100%
1 drugs

INA PHARMS's Top Competitors

INA PHARMS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

INA PHARMS Pipeline Snapshot

Active clinical trials for INA PHARMS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Dermatology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling